COVID-19 Jab Manufacturer To Close Multiple Sites

NEW – BioNTech to close three factories in Germany amid low capacity utilization and declining demand for mRNA injections, marketed against Covid.

— Disclose.tv (@disclosetv) September 28, 2026

Click to expand...

All told, BioNTech estimated that its decision to end those operations, including any CureVac sites abroad, will affect up to 1,800 jobs.

The three facilities in Germany being affected include manufacturing sites in Idar-Oberstein and Marburg, and the legacy headquarters in Tübingen by CureVac, which was acquired by BioNTech for $1.25 billion in 2025.

Separately, BioNTech is also set to end operations at its Singapore plant, bought from Novartis in 2022 amid an expansion spree of its mRNA footprint. The company has not provided an update on whether a new owner is in sight for the Singapore site.

In terms of financial impact, BioNTech expects its German operations consolidation efforts to generate 500 million euros in annual cost savings.

Click to expand...

In der Coronapandemie verdiente Biontech Milliarden, doch die Zeiten sind vorbei. Der Verkauf dreier Werke ist gescheitert, 1800 Mitarbeiter sind betroffen. https://t.co/okHAslMJ8R

— DER SPIEGEL (@derspiegel) September 28, 2026

Click to expand...

The restructuring, affecting up to 1,860 jobs, was part of a ⁠production transfer of its COVID-19 vaccine to partner Pfizer.

BioNTech, the initial inventor of the Western world’s most ⁠commonly used immunisation shot during the pandemic, said in March that its two co-founders would leave ⁠by the end of this year to start a new venture.

Click to expand...